--- title: "Azitra Unveils Positive Preclinical Results for ATR-01 in Ichthyosis Vulgaris" description: "Azitra, Inc. has announced positive preclinical results for its ATR-01 program, aimed at treating ichthyosis vulgaris. The engineered strain ATR01-616 secretes functional human filaggrin protein, demo" type: "news" locale: "en" url: "https://longbridge.com/en/news/261878897.md" published_at: "2025-10-20T12:02:40.000Z" --- # Azitra Unveils Positive Preclinical Results for ATR-01 in Ichthyosis Vulgaris > Azitra, Inc. has announced positive preclinical results for its ATR-01 program, aimed at treating ichthyosis vulgaris. The engineered strain ATR01-616 secretes functional human filaggrin protein, demonstrating effectiveness in reducing transepidermal water loss and repairing damaged skin in preclinical tests. Detailed findings will be presented at the BIO-Europe® conference in Vienna from November 3-5, 2025. Updates on clinical programs ATR-12 and ATR-04 were also provided, with more information on ATR-01's path to first-in-human studies expected in 2026. Azitra, Inc. has announced positive preclinical data for its ATR-01 program, which is being developed as a potential treatment for ichthyosis vulgaris. ATR-01 utilizes an engineered strain of S. epidermidis (ATR01-616) designed to secrete functional human filaggrin protein. Preclinical results demonstrated that ATR01-616 can produce active filaggrin, deliver it through the human stratum corneum, and repair damaged model skin. Specifically, the strain reduced transepidermal water loss in ex vivo pig skin models and showed positive pharmacological activity in multiple preclinical tests. Detailed data from these studies will be presented virtually at the BIO-Europe® conference, scheduled to take place in Vienna, Austria, from November 3-5, 2025. Azitra also provided updates on its clinical programs ATR-12 and ATR-04, with further information on the ATR-01 program and its path to first-in-human studies expected in 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Azitra Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY01652) on October 20, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) ### Related Stocks - [AZTR.US - Azitra](https://longbridge.com/en/quote/AZTR.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 英国的 SkinBioTherapeutics 公司正在调查前首席执行官，并发布了 2026 财年的利润警告 | 英国皮肤健康公司 SkinBioTherapeutics 周一表示，正在调查其前首席执行官，并认为他向董事会和审计师虚报了重要的财务信息。该公司表示，随之而来的财务重述将意味着 2026 财年的业绩将 “显著低于” 市场预期 | [Link](https://longbridge.com/en/news/276040470.md) | | 美股盘前热门交易：Jaguar Uranium 盘前涨 15.06%；Verde Clean Fuels 盘前涨 11.52% | Jaguar Uranium 盘前涨 15.06%；Verde Clean Fuels 盘前涨 11.52%；Rubico 盘前涨 44.28%；Enveric Biosciences 盘前涨 32.56%；Interactive Stre | [Link](https://longbridge.com/en/news/276336137.md) | | Anthropic 考虑锁定 10 GW 算力。（The Information） | Anthropic 考虑锁定 10 GW 算力。（The Information）风险提示及免责条款 市场有风险，投资需谨慎。本文不构成个人投资建议，也未考虑到个别用户特殊的投资目标、财务状况或需要。用户应考虑本文中的任何意见、观点或结论是 | [Link](https://longbridge.com/en/news/275347361.md) | | 10:07 ETAesthetic Management Partners 推出 DE\|RIVE® MD 抗衰老精华，这是一款植物基的外用产品，旨在促进皮肤健康 | Aesthetic Management Partners (AMP) 推出了 DE\|RIVE® MD 抗衰老精华，这是一款植物基的外用产品，旨在增强皮肤健康并对抗衰老迹象。这款创新的精华利用专有的植物源分泌因子来改善皮肤的紧致度、弹性、 | [Link](https://longbridge.com/en/news/276140160.md) | | 礼来公司称，Taltz 与 Zepbound 在皮肤清除和减重方面表现出'卓越的'效果 | 礼来表示，Taltz 与 Zepbound 结合可实现 “优越” 的皮肤清除和减重效果 | [Link](https://longbridge.com/en/news/276227704.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.